According to the latest financial results announced for the quarter and fiscal year ending March 31, 2026, Gland Pharma Ltd. delivered exceptional fourth quarter results with consolidated net profit surging 96.6% year-on-year to ₹366.6 crore compared to ₹186.5 crore in the prior year. The pharmaceutical company's consolidated revenue from operations reached ₹17,428 crore, reflecting a substantial 22% increase compared to Q4 FY25. For the entire fiscal year FY26, the company's base business revenue grew by 11% to ₹45,613 million, significantly bolstered by a 25% rise in revenue from its acquisition, Cenexi, which reached ₹18,693 million. The strong quarterly performance contributed to robust full-year results, with FY26 adjusted profit rising 50% to ₹10,455 million and consolidated revenue increasing by 14% to ₹64,307 million. Management noted that the robust performance was driven by a combination of new product launches, a ramp-up in the CDMO business, and cost-efficiency initiatives.
The company achieved significant operational improvements with EBITDA margin expanding to 29.4% from 24.4% in Q4 FY25, indicating enhanced operational efficiency and better cost management. This margin expansion of 480 basis points reflects the company's ability to optimize its business model and improve profitability metrics. The strong operational performance was supported by the company's diversified pharmaceutical portfolio and strategic market positioning, with the company primarily operating as a contract development and manufacturing organization (CDMO) specializing in injectable formulations. The successful integration of the French CDMO acquisition, Cenexi, which was completed in 2022, is now a major contributor to both revenue and profitability, with the CDMO segment contributing 46% to total revenue in Q4 FY26 and experiencing 36% year-on-year growth. The company also highlighted robust growth in its CDMO business, a key driver for revenue expansion.
The Board of Directors has recommended a final dividend of ₹20 per equity share (face value of ₹1 each), representing 2000% for FY26, subject to shareholder approval at the 48th Annual General Meeting scheduled for Tuesday, August 25, 2026. The record date for determining eligibility is Tuesday, August 11, 2026. This dividend declaration reflects the company's strong cash generation capabilities and commitment to returning value to shareholders. The company's balance sheet and cash flow metrics reflect a strengthening financial position, with net worth growing to ₹1,03,580 million in FY26 from ₹91,507 million in FY25, while ROCE improved to 12% from 9% and RONW rose to 11% from 8%.
Innovation continues to be at the core of operations, with ₹506 million invested in R&D during the quarter, primarily for complex product development and filings. The company achieved significant milestones with 31 product launches in the USA during FY26, including Dalbavancin and Brimonidine, with the company's U.S. presence further bolstered by eight new ANDA filings and 11 approvals in Q4. Additionally, the company has ramped up its Ready-to-Use (RTU) infusion bag portfolio, addressing a market opportunity of approximately $634 million in the U.S. The company's U.S. operations were supported by new CDMO contracts, including a complex Nano Drug Delivery System based injectable project, demonstrating the successful execution of cost-efficiency initiatives and robust demand across global markets. Looking ahead, the company continues to invest in its in-house complex pipeline and co-development partnerships to sustain its growth momentum and expand its presence in key global markets.
The company's growth strategy is showing tangible results through strategic initiatives including new product launches in the US market and expansions in manufacturing capacity. Gland Pharma has increased ampoule manufacturing capacity in Europe to meet growing demand and continues to diversify revenue streams through new product launches and CDMO contracts. The company's pipeline includes fifteen products in co-development, with commercialization anticipated in FY28. Key indicators to watch include progress on the new CDMO contract for a complex Nano Drug Delivery System and further utilization of the new European ampoule manufacturing line. Additionally, the launch of new molecules beyond the five introduced in US Q4 FY26 will be closely monitored as the company continues its growth trajectory in the injectables and CDMO services sector. However, the broader Indian pharmaceutical sector faces moderation in US market growth projections, with analysts forecasting a slowdown to 3-5% year-on-year for the US market in FY26, down from nearly 10% in FY25, citing global headwinds and regulatory uncertainties.
